It was possible that these novel COMT inhibitors can provide a starting point for synthetic efforts to generating related derivatives for further preclinical testing and new drugs used for the treatment of Parkinson’s disease, as adjuncts in L-dopa based therapy, or for the treatment of schizophrenia. This evidence concerns the gene COMT and Parkinson disease.